The results "support the involvement of type 2 cytokines in driving PN disease pathogenesis and the targeting of the IL-4/IL-13 axis as a novel therapeutic paradigm" for PN, the authors write.
1. Erythema, scaling, and itching caused by seborrheic dermatitis (SD) significantly decreased with roflumilast treatment. 2. Roflumilast treated for SD resulted in favourable local tolerability and safety profile. Evidence Rating Level: 1 (Excellent) Study Rundown: Seborrheic dermatitis (SD) is a chronic dermatosis characterized by erythematous, scaly, and pruritic patches and plaques in areas of high
New data indicate that once-daily roflumilast foam in treating seborrheic dermatitis may improve the lives of those in the 5% or more of the global population with the skin disease.
A silent disease characterized as a chronic cutaneous neuropathy, notalgia paresthetica has an unmet need yet to be fully understood and, dermatologists argue, an FDA-approved treatment could help improve understanding of the etiology and prevalence of this disease.